Profile Photo

David Furgeson, PhD

Assistant Dean & Professor
Department of Pharmaceutical Sciences

Windgate College of Medicine

Address: 8000 Campus Ave
Health Sciences Building, Box 41
Yourtown, WI 53999
Phone: Office Phone: 800.555.1212
My Social:

Spring semester office hours:

Expand All
Research Experience & Interests: David Furgeson, PhD
Research Support:

Susan Komen Breast Cancer Foundation, Department of Defense, University-wide AIDS Research Program, American Lung Association, Whittier Foundation.

Research Experience & Interests: David Furgeson, PhD
Research Interest:

Drawing upon research and management experience with large industry, start-up enterprises, academia, contract research, and government, Dr. Ferguson takes an interdisciplinary approach to pharmaceutical education, science and product development.  Dr. Ferguson collaborates with colleagues at national and international institutions in a variety of disciplines, including toxicology, analytical chemistry, chemical engineering, and materials science, with a therapeutic emphasis on central nervous system disorders, cancer, infectious disease, inflammation and nutrition.
Current research areas include:

  • formulation and drug delivery
  • rationally-designed and naturally occurring pharmaceuticals and excipients
  • veterinary products
  • nutraceuticals and functional foods
  • particles, materials and supercritical fluids
  • intellectual property and regulatory affairs
  • biocompatible polymers and medical devices
Educational Background: David Furgeson, PhD
Ph.D., Pharmaceutics and Medicinal Chemistry, University of Kentucky - 1992
Educational Background: David Furgeson, PhD
M.S., Toxicology, University of Kentucky - 1984
Educational Background: David Furgeson, PhD
B.S., Pharmacy, University of Rhode Island - 1981
Employment History: David Furgeson, PhD
Instructor, Huazhong Agricultural University, Microbiology and Immunology, School of Veterinary Medicine; 1985-1987
Employment History: David Furgeson, PhD
Assistant Professor, Huazhong Agricultural University, Microbiology and Immunology, School of Veterinary Medicine; 1987-1988
Employment History: David Furgeson, PhD
Research Assistant Professor, University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics; 1991-1996
Employment History: David Furgeson, PhD
Assistant Professor, University of Rhode Island, Department of Biomedical Sciences; 1997-2001
Employment History: David Furgeson, PhD
Associate Professor, University of Rhode Island, Department of Biomedical Sciences; 2001-2004
Employment History: David Furgeson, PhD
Leader of Functional Genomics and Proteomics, Wisconsin Biomedical Research Infrastructure Network; 2001-2005
Employment History: David Furgeson, PhD
Assistant Dean and Professor, Windgate College of Medicine, Department of Pharmaceutical Sciences; 2004-present
Publications: David Furgeson, PhD
PubMed Search - Furgeson

PubMed comprises more than 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Search for my Publications in PubMed - Furgeson

Publications: David Furgeson, PhD

Jyothi Matharu, Jun Oki, David R. Worthen, Quentin R. Smith, and Peter A. Crooks.  Regiospecific and conformationally restrained analogs of melphalan and dl-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.  Bioorganic and Medicinal Chemistry Letters 20:3688-3691, 2010.

Publications: David Furgeson, PhD

David R. Worthen, Aimee K. Bence, James P. Stables and Peter A. Crooks.  “In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.”  Bioorganic and Medicinal Chemistry Letters 19:5012-5015, 2009.

Publications: David Furgeson, PhD

Russell J. Mumper, Michael A. Bell, David R. Worthen, Richard A. Cone, Gareth R. Lewis,  Jeremy R. A. Paull, Thomas R. Moench.  Formulating a sulfonated antimicrobial dendrimer in a vaginal microbicidal gel having dual mechanisms of action.  Drug Development and Industrial Pharmacy35:515-24, 2009.

Publications: David Furgeson, PhD

Peter A. Crooks, David R. Worthen, William S. Caldwell, Gary D. Byrd and J. Donald deBezithy.  "Modern instrumental methods for studying mechanisms of toxicology."  In: Principles and Methods of Toxicology, Fifth Edition, ed. A. Wallace Hayes, Taylor and Francis, 2008, pp. 2041-2112.

Publications: David Furgeson, PhD

David R. Worthen and Peter A. Crooks. "The radiosensitizing effects of L-canavanine." In: Herbal Radiomodulators: Applications in Medicine Homeland Defense and Space, ed. Rajesh Arora, CABI Publishing, UK, 2008, pp. 255-270.

Publications: David Furgeson, PhD

Xie M, Yang D, Wu M, Xue B, Yan B (2003) Mouse carboxylesterase M-LK rapidly hydrolyzes antitumor prodrug CPT-11 and the N-terminal three quarter sequence determines substrate selectivity.Drug Metab Dispos.  31: 21-27.

Publications: David Furgeson, PhD

Sachdeva K, Yan B, Chichester CO (2003) Lipopolysaccharide and cecal ligation/puncture differen­ti­ally affect the subcellular distribution of the pregnane X receptor but consistently cause suppression of its target gene CYP3A. Shock. 19: 470-475.

Publications: David Furgeson, PhD

Li Y, Xie M, Song X, Gragen S, Sachdeva K, Wan Y, Yan B (2003) DEC1 negatively regulates the expression of DEC2 through binding to the E-box in the proximal promoter. J Biol Chem. 278: 16899-16907.

Publications: David Furgeson, PhD

Wyde ME, Bartolucci E, Ueda A, Zhang H, Yan B, Negishi M, You L (2003) The environmental pollutant DDE induces hepatic cytochrome P450 2B and 3A expression through activating the constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Mol Pharmacol. 64: 474-481.

Publications: David Furgeson, PhD

Nam NH, Pitts R, Sun G, Sardari S, Tiemo A, Xie M, Yan B, Parang K (2004) Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorgan & Med Chem. 12: 779-787.

Publications: David Furgeson, PhD

Jabar A. Faraj, Rosella Dorati, Aurelie Schoubben, David Worthen, Francesca Selmin, Yilmaz Capan, Kai Leung and Patrick P. DeLuca.  "The development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system."  AAPS PharmSciTech 8(1) Article 26, 2007.

Patents: David Furgeson, PhD
“Process of making aripiprazole particles.” US Patent 7,507,823, 2009.

A method of preparation of crystalline aripiprazole monohydrate includes the use of solution enhanced dispersion by supercritical fluid. Specifically, water is introduced to a stream of supercritical fluid which is then allowed to mix with a stream including a mixture including aripiprazole and a solvent. The mixing results in the substantially simultaneous dispersion and extraction of the aripiprazole from the mixture by the supercritical fluid.

See full patent details at Google Patents - 7,507,823, 2009

Patents: David Furgeson, PhD
Agmatine and agmatine analogs in the treatment of epilepsy, seizure and electroconvulsive disorders. US Patent 7,816,407, 2010.

Pharmaceutical preparations containing of agmatine, congeners, analogs or derivatives thereof for use in preventing or treating epilepsy, seizures and other electroconvulsive disorders are provided. Embodiments include administering an effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof to a human subject in need of treatment or prevention of epilepsy, seizure or other electroconvulsive disorder to treat, reduce, or prevent the disorder in the subject.

See full patent details at Google Patents - US Patent 7,816,407

Association & Society Membership: David Furgeson, PhD
AAAS (American Association for the Advancement of Science)

The American Association for the Advancement of Science, "Triple A-S" (AAAS), is an international non-profit organization dedicated to advancing science around the world by serving as an educator, leader, spokesperson and professional association. In addition to organizing membership activities, AAAS publishes the journal Science, as well as many scientific newsletters, books and reports, and spearheads programs that raise the bar of understanding for science worldwide.

AAAS Website

Association & Society Membership: David Furgeson, PhD
SOT (Society of Toxicology)

The Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing the great variety of scientists who practice toxicology in the US and abroad. SOT is committed to creating a safer and healthier world by advancing the science of toxicology. The Society promotes the acquisition and utilization of knowledge in toxicology, aids in the protection of public health, and facilitates disciplines. The Society has a strong commitment to education in toxicology and to the recruitment of students and new members into the profession.

Resource Link

Association & Society Membership: David Furgeson, PhD
Shock Society

The mission statement of the Shock Society is to improve the care of victims of trauma, shock, and sepsis, through:

  • Promoting clinically relevant research into the basic biology of trauma, shock, and sepsis
  • Providing a multidisciplinary forum to integrate and disseminate new knowledge in trauma, shock, and sepsis
  • Promoting the education and mentoring of the next generation of investigators in the field of trauma, shock, 
    and sepsis
Resource Link

Association & Society Membership: David Furgeson, PhD
The Endocrine Society

The mission of The Endocrine Society is to advance excellence in endocrinology and promote its essential and integrative role in scientific discovery, medical practice, and human health.

Resource Link

Association & Society Membership: David Furgeson, PhD
ISSX (International Society of Xenobiotics)

The founding of ISSX arose from discussions initiated by Dr. Bruce Migdalof at the 1980 Gordon Conference on Drug Metabolism.  Bruce, Fred DiCarlo, John Baer, and Ina Snow who were to become the founders of ISSX, had discussions with many attendees of the conference and confirmed their feelings for the need for an international society devoted to the study of the metabolism of foreign compounds.  The organizing committee, chaired by Bruce Migdalof, met later that year and launched ISSX in 1981.

Resource Link

Association & Society Membership: David Furgeson, PhD
Mid-Atlantic Society of Pharmacology

MAPS is a constituent chapter of the American Society for Pharmacology and Experimental Therapeutics (ASPET) that was formed in 1987 by a group of local pharmacologists (Warren Chernick, Jay Roberts, Paul Bianchi, and J. Bryan Smith). Their objective was to provide scientists in our geographical area (New Jersey, Pennsylvania and Delaware) with a forum for meeting on a regular basis to discuss recent advances in pharmacology, related medical disciplines and therapeutics. MAPS has always tried to be a "student-friendly" organization. With this in mind, undergraduate students, graduate students, and postdoctoral fellows were encouraged to join at reduced membership rates. The interaction of students and postdoctoral fellows with local industrial and academic scientists was strongly encouraged and, in order to help achieve this, the annual poster competition was instituted. From 1987 to 1997, the society hosted two meetings a year and beginning in 1998 it was decided that the society would host one annual meeting, held in the Fall.

Resource Link

Book & Article Contributions: David Furgeson, PhD
Review Articles:

Yan B (1988) Lecture 1: Introduction in Veterinary Epidemiology. Chinese J Vet Med. 14(5): 43-44.

Yan B (1988) Lecture 2: Conditions of Pathogenesis in Veterinary Epidemiology. Chinese J Vet Med.14(6): 55-56.

Yan B (1988) Lecture 3: Distribution of Diseases in Veterinary Epidemiology. Chinese J Vet Med.14(8): 52-53.

Yan B (1988) Lecture 4: Statistics in Veterinary Epidemiology. Chinese J Vet Med. 14(9): 46-48.

Yan B (1988) Lecture 5: Methodology in Veterinary Epidemiology. Chinese J Vet Med. 14(10): 41-43.

Yan B (1988) Lecture 6: Epidemiologic Modeling in Veterinary Epidemiology. Chinese J Vet Med.14(11): 46-48.

Book & Article Contributions: David Furgeson, PhD
Book Chapters:

Zheng H and Yan B (2001) Molecular Toxicology in Toxicology (Editor: Lijie Fu), pages 165-188, Shanghai Scientific Press, Shanghai.

Yan B (2004) Introduction to molecular biology and techniques in Molecular Neurotoxicology: Transcription and Signaling Targets (Editor: Nasser Zawia), pages 9-34, CRC Press, Florida.

Student Development: Preceptorships / Mentorships: David Furgeson, PhD

I am very pleased to have been able to supervise some truly outstanding graduate students, and the opportunity to have worked so closely with them has surely been one of the most rewarding aspects of my career. How pleasant it has been in each case to see our interactions transform over the years from one of teacher and student to one of earnest colleagues, as each of them gained intellectual power over their dominion. I look forward to many years of interactions with them; surely I shall continue to learn a great deal from them.

My current Ph.D. student is:
Eric Pinchot, Windgate Graduate Center

My graduate students who have completed their Ph.D. degree are:
Heidi Hall, Ph.D. 2012, Windgate Graduate Center
James Burke, Ph.D. 2011, Windgate Graduate Center
Kevin Dark, Ph.D. 2010, Windgate Graduate Center
Irving Denault, Ph.D. 2007, Windgate Graduate Center
Allison Kane, Ph.D. 2006, Windgate Graduate Center
Claire Lieu, Ph.D. 2004, Windgate Graduate Center 

I was the Master’s Thesis Supervisor of:
Lloyd Scriber M.Sc. 2007,  Windgate Graduate Center

I was on the thesis committee for the following students:
James Zeppy, Ph.D. 2012,  Windgate Graduate Center
Howard Green, Ph.D. 2010,  Windgate Graduate Center
Peter Gerber, Ph.D. 2009,  Windgate Graduate Center
Ellen Wall, Ph.D. 2008,  Windgate Graduate Center
Erica Gagnon, Ph.D. 2007,  Windgate Graduate Center
Dustin Carr, Ph.D. 2006,  Windgate Graduate Center
Stephanie McKnight, Ph.D. 2004,  Windgate Graduate Center
Hillary Soares, Ph.D. 2000,  Windgate Graduate Center

Committees & Boards: David Furgeson, PhD

2003 International Wellcome Trust 2004 USDA Special Research Grants Program 2004 Kentucky Science & Technology Foundation 2005 NIH Study Section XNDA

Grants: David Furgeson, PhD
TAACCCT Grant Award (Round 2 & Round 3): 2012 & 2013

Co-wrote the TAACCCT Grant for the Northeast Consortium. The TAACCCT Technology Support Package serves as the cornerstone of our TAACCCT technology platform and process management.

In 2009, the American Recovery and Reinvestment Act amended the Trade Act of 1974 to authorize the Trade Adjustment Assistance Community College and Career Training (TAACCCT) Grant Program. On March 30, 2010, President Barack Obama signed the Health Care and Education Reconciliation Act, which included $2 billion over four years to fund the TAACCCT program.

TAACCCT provides community colleges and other eligible institutions of higher education with funds to expand and improve their ability to deliver education and career training programs that can be completed in two years or less, are suited for workers who are eligible for training under the TAA for Workers program, and prepare program participants for employment in high-wage, high-skill occupations. Through these multi-year grants, the Department of Labor is helping to ensure that our nation's institutions of higher education are helping adults succeed in acquiring the skills, degrees, and credentials needed for high-wage, high-skill employment while also meeting the needs of employers for skilled workers. The Department is implementing the TAACCCT program in partnership with the Department of Education.

TAACCCT Grant Support Package

Grants: David Furgeson, PhD
TAACCCT Grant Support Package PDF

Grants: David Furgeson, PhD
Completed Grants/Written and Co-written:

Fox Chase Cancer Center Grant Supported Pilot Project: “Sleeping Beauty Based Ovarian Cancer Gene Discovery”;10/2010-09/2011; Co-Investigator

SPORE (Specialized Program in Ovarian Cancer Research Excellence) Pilot Project:     “Noncanonical Roles of CRBP1 in Ovarian Oncogenesis”; 08/2009-07/2010; Co-Investigator

Research Funding Agreements(2) for preclinical evaluation of antibody-based therapy in an in-vivo model of human ovarian cancer; 2009-2011 Co-P.I.

Assisted in writing of a successful NIH RO1 CA107195; Loss of Vitamin A Metabolism in Ovarian Oncogenesis; P.I. Thomas C. Hamilton; 06/2005 – 04/2010

Teaching Experience: David Furgeson, PhD

PHP 1020 Principles of Pharmacotherapy

Pharmacology is one of the vital disciplines in biomedical sciences. It employs the multidisciplinary knowledge in biochemistry, cell biology, chemistry, genetics, neuroscience, pathology, physiology, toxicology, and clinical medicine, to elucidate the mechanisms of action of drugs in treating human diseases. This course represents a collective endeavor of our faculty to the teaching of graduate and senior undergraduate students in UR. It focuses on the fundamental principles of pharmacology, neuropharmacology, cardiovascular pharmacology, and contemporary approaches to drug discovery and design.

PHP 1930 Advanced Pharmacotherapeutics

Advanced pharmacotherapeutics provides the advanced practice nurse a rational basis for pharmacologic management of clients. The principles of pharmacology and the process of pharmacological reasoning for primary care of common acute and chronic illnesses will be presented. The core topics will examine advanced nursing roles in the management of pharmacotherapeutics for clients across the life-span in rural and urban underserved communities.

Conference & Trade Show Attendance: David Furgeson, PhD
Annual Shock Meeting

2002, 2011

Resource Link

Conference & Trade Show Attendance: David Furgeson, PhD
International Conference of Microsomal Enzymes

Attended 2005, 2009, 2012

Conference & Trade Show Attendance: David Furgeson, PhD
SOT (Society of Toxicology)

Attended annually 1998 - 2013 

Resource Link

Honors & Awards: David Furgeson, PhD
Honors & Awards:

1995 Molecular Biology Section Award, Society of Toxicology (USA)
1997 Faculty Development Award, University of Rhode Island
1997 Career Development Award, National Institutes of Health
1998 New Investigator Award, America Association of College of Pharmacy
1998 Co-recipient of best poster from Northeast Chapter of Toxicology
1999 Co-recipient of Best Poster from New England Society of Pharmacology
2000 Outstanding Researcher Award, University of Rhode Island
2003 Co-recipient of Best Paper Award, the America Chinese Society of Toxicology
2003 Co-recipient of Best Paper, the International Society of Study of Xenobiotics 

Publication & Journal Subscriptions: David Furgeson, PhD

SHOCK®: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches includes studies of novel therapeutic approaches, such as immunomodulation, gene therapy, nutrition, and others. The mission of the Journal is to foster and promote multidisciplinary studies, both experimental and clinical in nature, that critically examine the etiology, mechanisms and novel therapeutics of shock-related pathophysiological conditions. Its purpose is to excel as a vehicle for timely publication in the areas of basic and clinical studies of shock, trauma, sepsis, inflammation, ischemia, and related pathobiological states, with particular emphasis on the biologic mechanisms that determine the response to such injury. Making such information available will ultimately facilitate improved care of the traumatized or septic individual.

Resource Link

Publication & Journal Subscriptions: David Furgeson, PhD
ToxSci Journal

Toxicological Sciences is the official journal of the Society of Toxicology (SOT) and all proceeds from the journal remain within the scientific community. Toxicological Sciences provides a major source of funding for the SOT’s programs benefitting researchers in academia, industry, government, and other scientific organizations. By subscribing to Toxicological Sciences, submitting papers, and reviewing submissions, you make a direct contribution to the toxicology research community.


Speaking Engagements: David Furgeson, PhD
Invited Speaking:

1. New York Medical College, NY (1989): Construction and differential screening of two cDNA libraries derived from melanoma cell lines.

2. University of Kansas Medical Center, KS (1993): Molecular cloning and expression of rat carboxylesterases.

3. University of Kansas Medical Center, KS (1994): Molecular biology of carboxyl­esterases in rat.

4. University of Kansas Medical Center, KS (1994): Identification of a secretory form of carboxylesterase synthesized in rat liver.

5. University of Kansas Medical Center, KS (1994): Approaches to search response genes.

6. University of Kansas Medical Center, KS (1995): Molecular basis for the existence of multiple forms of rat carboxylesterases.

7. Auburn University, AL (1995): Rat Carboxylesterases: Molecular basis for multiplicity and relationship to acetyl­cholin­esterases.

8. 7th North American ISSX Meeting (1996): Structure of carboxylesterases and the molecular basis for multiple forms (symposium).

9. Huazhong Agricultural University (1999): Mammalian carboxylesterases: structure, biosynthesis and xenobiotic regulation.

10. Life Science and Clinical Medicine in Beijing (2000): Pregnane X receptor mediated regulation of genes encoding drug-metabolizing enzymes.

11. Beijing Medical University (2000) Signaling of pregnane X receptor requires involvement of multiple nuclear proteins.

12. Pfizer Corporation (2000) Toxicological significance of carboxylesterase and signaling of pregnane X receptor.

13. Chemical Institute of Industrial Toxicology (2000) Role of the pregnane X receptor in cytochrome P450 induction.

14. University of Rhode Island, Department of Biochemistry, Microbiology and Molecular Genetics (2000) Receptor mediated induction of drug-metabolizing enzymes.

15. Avon Products Inc. (2000) Application of promoter reporter arrays in screening drug candidate compounds.

16. MultiCell Associates, Inc. (2001) Xenobiotic regulation of drug-metabolizing enzymes in primary and continuous cells.

17. Sino-American Pharmaceutical Professionals Association (2001) Regulation of Drug-metabolizing enzymes by nuclear receptor activation: serious consideration in drug development.

18. Unilever Inc. (2001) Skin signaling and assays for cosmetic products development.

19. Chinese Academy of Sciences (2001) Signaling of nuclear receptors in responding to drug and environmental chemicals.

20. Rhode Island Hospital (2001) Signaling of liganded and unliganded transcription factors: the pregnane X receptor in xenobiotic response and colon carcinoma associate factor in oncogenesis.

21. Providence College (2002) Oncogenic significance of DEC1 transcription factor.

22. Rhode Island Biomedical Infrastructural Network (2003) Roles of DEC transcription factors.

23. Rhode Island Hospital/Brown University, Department of Surgery (2003) The Pregnane X Receptor: Beyond drug-metabolism.

24. Rhode Island Hospital/Brown Medical School, Department of Orthopaedic Biology (2003) DEC trans­cription factors: Do it all.

25. Huazhong Agricultural University (2004) Signaling of PXR and DEC1 transcription factors.

26. Asian-Pacific Conference on Tumor Biology and Makers (2004) Oncogenic involvement of DEC1 transcription factor

27. Beijing University School of Medicine (2004) Natural products: Where we go from here?

28. University of Rhode Island, College of Pharmacy (2005) Genomic and structural bases for drug-drug interactions and oncogenic involvement of DEC1 transcription factor

29. CellzDirect Biotechology (2005) Prediction of pharmacokinetic interactions based on hydrolytic biotransformation

30. University of Rhode Island, Department of Biomedical & Pharmaceutical Sciences (2005) Hydrolytic biotransfor­ma­tion of aspirin (Pharmaceutical seminar series)

31. University of Kansas Medical Center (2005) Pharmacogenes: what are they?

32. Roger Williams Medical Center, COBRE/Research Department Seminar Series (2005) Molecular clock and oncogenesis: Is there a connection?

Speaking Engagements: David Furgeson, PhD
Conference Presentations:

1. Yan B, Morgan EW, Parkinson A (1990) Immunocytochemical localization of two carboxylesterases in rat liver, kidney and testis. Toxicologist 10: 323.

2. Morgan EW, Yan B, Parkinson A (1990) Purification and characterization of two rat liver microsomal carboxylesterases: studies on their regulation and tissue distribution. Presented at the VIIIth International Symposium on Microsomes and Drug Oxidation, Stockholm, Sweden. 

3. Yan B, Morgan EW, Parkinson A (1991) Carboxylesterase activities in human liver, kidney and testis. Toxicologist 11: 228.

4. Yan B, Brady M, Parkinson A (1992) Comparison of rat liver and testicular carboxylesterase by recombinant DNA techniques. Toxicologist 12: 330.

5. Yan B, Brady M, Parkinson A (1993) Nucleotide sequencing of a cDNA encoding a carboxylesterase present in rat liver and kidney microsomes. Toxicologist 13: 385.

6. Yan B, Yang D, Parkinson A (1994) Cloning and nucleotide sequencing of a rat liver carboxylesterase. Toxicologist 14: 1300.

7. Downing GJ, Yan B, Poisner A (1994) ß-Adrenoceptor activation stimulates human placental renin gene expression. Research Forum KUMC 22: 1.

8. Yan B, Parkinson A (1994) Identification of a secretory form of carboxylesterase in rat liver. Research Forum KUMC 22: 39.

9. Parkinson A, Yan B (1994) Purification and cloning of rat carboxylesterases. International Conference of Microsomal Enzymes 12: 7.

10. Yan B, Yang D, Parkinson A (1995) Molecular biology of rat liver carboxyl­esterases. Toxicologist15: 822.

11. Yang D, Yan B, Parkinson A (1995) Cloning and expression of hydrolase S, a serum carboxylesterase secreted by rat liver. Toxicologist 15: 824.

12. Fan F, Yan B, Wood G, Viluksela M, Rozman RR (1996) Cytokines (IL-1ß and TNF-a) in relation to biochemical and immunological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats.Toxicologist 16: 797.

13. Yan B, Parkinson A (1996) Structure of carboxylesterases and molecular basis for multiple forms.ISSX Proceedings 10: 6.

14. Hamilton GA, Oberfield JL, Moore LB, Jolly S, Coon DJ, McKee DD, Lehmann JM, Moore JT, Yan B, Laethem RM, Kliewer SA, LeCluyse EL (1999) PXR-mediated species difference in CYP3A gene regulation. ISSX Proceedings 13: 45.

15. Zhang H, Li Y, Yan B (1999) transactivation activity of rat PXR and the corresponding chimeric receptor. Northeast Society of Pharmacology 26.

16. Zhang H, Song L, Liu L, Matoney L, Yan B (2000) Immunochemical characterization of rat pregnane X receptor. Toxicologist 20: 498.

17. Zhu W, Song L, Li Y, Zhang H, Matoney L, Yan B (2000) Non-lytic expression of xenobiotic-metabolizing enzymes in insect cells. Toxicologist 20: 1750.

18. Zhang H, Li Y, Matoney L, Yan B (2000) A truncated PXR mutant potentiates the transactivation activity of the corresponding wild type PXR. ASBMB/ASPET. L106.

19. Chichester C, Sachdeva K, McKindley D, Zhang H, Li Y, Yan B (2000) Effect of LPS mediated blockade of PXR Translocation on CYP3A expression. Annual Shock Meeting

20. Zhang H, Yan B (2001) Human and rat pregnane X receptors differentially activate synthetic reporter genes. Toxicologist 40: 179.

21. Yang D, Li Y, Yuan X, Matoney L, Yan B (2001) Regulation of rat carboxylesterase expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves multiple signaling pathways. Toxicologist 40: 2117.

22. Li Y, Jones B, Wan Y, Zhang H, Yan B (2001) Effect of UVB irradiation on the expression of skin drug-metabolizing enzymes Toxicologist 40: 294.

23. You L, Bartolucci E, Fryczynski M, Zhang H, Yan B (2001) DDE activates the orphan nuclear receptor PXR and induces 6beta-testosterone hydroxylase. 83rd Endocrine Society Annual Meeting. P3-653.

24. Yang D, Yan B (2002) Mouse carboxylesterases M-LK and TGH: molecular cloning, tissue distribution, xenobiotic regulation and evidence for the N-terminal sequence to determine the substrate specificity. Toxicologist 41: LB135.

25. Xie M, Yan B (2002) Responsiveness of heat shock protein genes to a range of herbal supplements. Toxicologist 41: 933.

26. Zhang W, Yan B (2002) Human and rodent carboxylesterases: immunorelatedness, overlapping sub­strate specificity, differential sensitivity to serine inhibitors, and tumor-related expression.Toxicologist 41: LB 134.

27. Zhang H, Yan B (2002) The N-terminal region of rat pregnane X receptor potentiates the transcription of the wild-type receptor and corepressor SuncoR reverses the potentiation effect.Toxicologist 41: 202.

28. Li Y, Xie M, Yan B (2002) DEC1 basic helix-loop-helix differentially regulates genes encoding carboxylesterases and cytochrome P450. Toxicologist 41: 200.

29. Wan YS, Yan B (2002) Utilization of Chinese herbs to attenuate cell signalings important for cancer development. International Conference on Chinese Medicine, Chengdu, China

30. Chiu C, Turlington A, Blanco M, Myne P, Lin JY, Yan B, Vezeridis M, Wan YS (2003) Ovarian cancer cells do not migrate in response to EGF largely due to the inactivation of ERK. AACR Annual Meeting

31. Nam NH, Pitts R, Sun G, Sardari S, Tiemo A, Xie M, Yan B, Parang K (2003) Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Cordon Research Conference on Bioorganic Chemistry.

32. Song X, Yan B (2003) The pregnane X receptor binds to response elements in genomic context and activator-dependent manners. International Society for the Study of Xenobiotics. 227.

33. Wan Y, Yan B (2003) Intramolecular disulfide bridges are required for folding hydrolase B into a cataly­ti­cally active conformation. International Society for the Study of Xenobiotics. 228.

34. Gragen SM, Yan B (2003) Selective hydrolysis of RAR activator tazarotene by human skin carboxyl­esterases. International Society for the Study of Xenobiotics. 229.

35. Li Y, Sachdeva K, Yan B, Chichester CO (2003) Clofibrate synergistically increases the induction of CYP3A1/23 by pregnenolone 16a-carbonitrile. International Society for the Study of Xenobiotics. 230.

36. Xie M, Yan B (2003) Rat NTE-related esterase hydrolyzes phenyl valerate through a serine catalytic machinery. International Society for the Study of Xenobiotics. 231.

37. Sachdeva K, Yan B, Chichester CO (2003) Kavalactones differentially induce cytochrome P4503A1/23 and activate the pregnane X receptor.  International Society for the Study of Xenobiotics. 232.

38. Li Y, Wyde M, Kirwan S, Laughter A, Bartolucci-Page E, Gaido K, Yan B (2004) Di-butyl phthalate activates the nuclear receptors CAR and PXR and enhancers the expression of CYP2B1 and 3A1 in maternal and fetal liver in the rat. Toxicologist 43: 1374.

39. Pope C, Karanth S, Liu J, Shaikh J, Yan B (2004) Human liver carboxylesterase during postnatal maturation and its sensitivity to chlorpyrifos oxon. Toxicologist 43: 1840.

40. Xia JP, Song XZ, Bi ZG, Yan B, Wan YS (2004) EGCG inhibits UV-induced kB nuclear translocation and IL-6 secretion in cultured human keratinocytes. Annual Meeting of Society of Investigative Dermatology.

41. Q Wang, ZG Bi, Yan B, Wan YS (2004) Construction of full length cDNA differential display libraries for genital warts based on long template PCR and full-length cDNA suppression subtractive hybridization (FL-cDNA-SSH). Annual Meeting of Society of Investigative Dermatology.

42. Wang F, Bi ZG, Wang Q, Li GF, Wang XJ, Zhang ZS, Yan B, Wan YS (2004) Cloning and Expression of E6 and E7 Gene of Human Papilloma Virus Type II in E. coli. Annual Meeting of Society of Investigative Dermatology.

43. Sun WL, Bi ZG, Yan B, Wan YS(2004) Evaluation of histamine-releasing activity in the sera of patients with chronic urticaria. Annual Meeting of Society of Investigative Dermatology.

44. Song ZS, Xia JP, Bi ZG, Yan B, Wan YS (2004) Aloin attenuates UVA-induced AP1 activation and MMP expression in cultured human skin fibroblasts. Annual Meeting of Society of Investigative Dermatology.

45. Turlington A, Chiu C, Myne P, Bi ZG, Li Y, Yan B, Wan YS (2004) Reciprocal regulation of DEC1 and HIF1a in response to UV irradiation in cultured human Keratinocytes. Annual Meeting of Society of Investigative Dermatology. 

46. Turlington A, Myne P, Chiu C, Blanco A, Bi ZG, Yan B, Wan YS (2004) Insensitivity to oxidative stress and hyper-activation of AKT contribute to anomalous invasiveness of human melanoma cells. Annual Meeting of Society of Investigative Dermatology.

47. Fan WX, Zhou NH, Bi ZG, Yan B, Wan YS (2004) Expression of pIRES2-EGFP-hVEGF165 in HaCaT cells and pig hair pappilae cells. Annual Meeting of Society of Investigative Dermatology.

48. Wan YS, Yan B (2004) Selective Hydrolysis of RAR Activator Tazarotene By Human Skin Carboxylesterase. Annual Meeting of Society of Investigative Dermatology.

49. Yang J, Qiu L, Zhou C, Sheffler E, Derby S, Bi Z, Yan B, Wan Y (2005) DEC1 protects against UV-induced cell death in cultured human keratinocytes. Annual Meeting of Society of Investigative Dermatology.

50. Qiu L, Zhou C, Yang J, Sheffler E, Derby S, Bi Z, Yan B, Wanebo H, Wan Y (2005) Up-regulation of survivin mediated by transient activation of EGFR/AKT pathway contributes to reduced sensitivity of human melanoma cells to betulinic acid. Annual Meeting of Society of Investigative Dermatology.

51. Wang XY, Bi ZG, Yan B, Wan YS (2005) Protective effect of ()-epigallocatechin-3-gallate on UVA-induced inhibition of dermal fibroblasts collagen synthesis. Annual Meeting of Society of Investigative Dermatology.

52. Wang XY, Bi ZG, Yan B, Wan YS (2005) L-1 receptor antagonist inhibits MMP-1 production of UVA-irradiated human skin fibroblasts cultured with medium from UVB-irradiated keratinocytes. Annual Meeting of Society of Investigative Dermatology.

53. Wang XY, Bi ZG, Yan B, Wan YS (2005) IL-1 augments MMP-1 and MMP-2 production in UVA-irradiated human dermal fibroblasts. Annual Meeting of Society of Investigative Dermatology.

54. Wang XY, Bi ZG, Yan B, Wan YS (2005) The paracrine effect of UVB-irradiated human keratinocytes culture medium on MMP-1 production of UVA-irradiated dermal fibroblasts. Annual Meeting of Society of Investigative Dermatology.

55. Xiang W, Wang F, Bi ZG, Yan B, Wan YS (2005) Construction and expression of plasmid co-expressing human papillomavirus type 11 E7 and human IFNg-2b. Annual Meeting of Society of Investigative Dermatology.

56. Wang F, Bi ZG, Li GF, Wu HW, Wang Q, Liu F, Wang XJ, Zhang ZS, Yan B, Wan YS (2005)Generation of Recombinant Adenovirus Vectors of Human Papillomavirus Type 11 E7 Gene and Its Expression in Eukarytoic Cells. Annual Meeting of Society of Investigative Dermatology.

57. Wang P, Bi ZG, Jing J, He J, Yan B, Wan Y(2005) p16INK4a Protein expression and gene inactivation in human skin tumors. Annual Meeting of Society of Investigative Dermatology.

58. Chen B, Bi ZG, Yan B, Wan YS (2005) Protein profiling of human fibroblasts and keratinocytes by two dimensional gel electrophoresis. Annual Meeting of Society of Investigative Dermatology.